MDACC Study No:2010-0841 ( NCT No: NCT01266967)
Title:BRF113929: A Phase II Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Na´ve and Previously Treated Subjects with BRAF Mutation-Positive Metastatic Melanoma to the Brain
Principal Investigator:Michael Davies
Treatment Agent:GSK2118436
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if dabrafenib can help to
control metastatic melanoma that has spread to the brain. The safety of this
drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase II
Treatment Agents:GSK2118436
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:GSK
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Davies
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults